Bill Gross warns on gold momentum as regional bank stocks tumble
This article summarizes the most significant insider buying and selling activities reported for US stocks on Friday, September 22, 2025.
Top Insider Buys:
• Biodesix Inc (NASDAQ:BDSX): Director Jack W. Schuler made a substantial purchase of 15,317 shares, valued at $92,551. The transaction occurred on September 17, 2025, with share prices ranging from $5.825 to $6.15. This acquisition increased Schuler’s total holdings to 1,235,644 shares. The purchase is notable given the stock’s significant decline, with a -81.1% return over the past year and a current market capitalization of $56.16 million.
• Archrock, Inc. (NYSE:AROC): Director Jason C. Rebrook acquired 10,000 shares on September 18, 2025, at prices between $24.11 and $24.20 per share. The total value of the purchase amounted to $241,670. Following the transaction, Rebrook directly owns 64,511 shares. Archrock, with a market capitalization of $4.3 billion, has demonstrated financial stability with a 12-year track record of consistent dividend payments and a healthy current ratio of 1.81x.
• Nextnrg (NASDAQ:NXXT): CEO Michael D. Farkas made a significant purchase of 1,000,000 shares at $1.67 per share, totaling $1,670,000. The transaction occurred on September 18, 2025, as the stock traded at $1.77, having fallen over 37% in the past six months. Following the purchase, Farkas directly and indirectly owns 75,254,300 shares of the $222 million market cap company.
• NextDecade Corp (NASDAQ:NEXT): Director Edward Andrew Scoggins Jr. bought 15,000 shares on September 18, 2025, at a weighted average price of $6.4557, for a total value of $96,835. The purchase comes as the stock trades near $6.45, down approximately 29% over the past six months. Following the transaction, Scoggins directly owns 200,070 shares of NextDecade.
Top Insider Sells:
• Apellis Pharmaceuticals (NASDAQ:APLS): Director Dunlop A. Sinclair indirectly sold 31,092 shares on September 19, 2025, for $713,561. The sales were executed under a pre-arranged Rule 10b5-1 trading plan, with prices ranging from $22.73 to $23.27.
• Natera, Inc. (NASDAQ:NTRA): Executive Chairman Matthew Rabinowitz sold shares totaling $9,016,668 on September 18 and 19, 2025. The sales involved multiple transactions with prices ranging from $180.0 to $181.282 per share, as the stock trades near its 52-week high of $183.
• United Therapeutics Corp (NASDAQ:UTHR): Director Judy D. Olian sold 1,800 shares on September 19, 2025, at a weighted average price of $415.4266, resulting in a total transaction value of $747,767. The $18.9 billion biotech company’s stock has gained over 33% in the past six months.
• Brady Corp (NYSE:BRC): President and CEO Russell Shaller sold 23,743 shares of Class A Common Stock on September 18, 2025, for approximately $1.9 million. The sales were executed at prices ranging from $80.00 to $80.64 per share, near the stock’s 52-week high of $84.03.
Investors should stay tuned to insider buying and selling activities as they can provide valuable insights into a company’s prospects. While insider transactions alone should not be the sole basis for investment decisions, they can offer additional context when combined with fundamental and technical analysis. It’s important to consider the overall market conditions, company performance, and individual circumstances of insiders when interpreting these transactions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.